Logo

454 s Q1 Revenue Surges, Though Grant Receipts Slip 29 Percent

Apr 27, 2006

NEW YORK, April 27 (GenomeWeb News) - 454 Life Sciences generated $8.8 million from sales of instrument and reagents, fee-for-service sales, and milestone and royalty payments, up from $1.3 million year over year

 

The majority-owned CuraGen subsidiary also said revenue from grants slipped 29 percent in the period to $500,000 from $700,000 year over year.

 

Breaking down the numbers for this period, CuraGen said 454 generated nearly $4.5 million in product sales while the 454 SequencingCenterbrought in approximately $2.4 million.

 

In its statement today, CuraGen did not disclose 454's figures from the first quarter 2005; the information was obtained from CuraGen's website.

Breaking News
The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.